Dae-Sung Kim1, Jun-Tae Choi1, Cheong Bi Kim2, Yu-Ra Shin1, Pil-Gu Park2, Hyemi Kim2, Jae Myun Lee3, Jung-Hwan Park4. 1. Department of Bionano Technology and Gachon BioNano Research Institute, Gachon University, Seongnam-si, Gyeonggi-do, Republic of Korea. 2. Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea. JAEMYUN@yuhs.ac. 4. Department of Bionano Technology and Gachon BioNano Research Institute, Gachon University, Seongnam-si, Gyeonggi-do, Republic of Korea. pa90201@gachon.ac.kr.
Abstract
AIMS: Crosslinked hyaluronic acid (X-linked HA) is not suitable for making microneedles because of the low fluidity of X-linked HA hydrogel. Microneedles were fabricated using X-linked HA nanoparticles (X-linked HA-NPs) to utilize the sustained drug delivery capability of X-linked HA-NPs and to obtain the processability advantages of X-linked HA. METHOD: The puncture performance of a microneedle array patch (MAP) made of crosslinked hyaluronic acid nanoparticles (X-linked HA-NP-MAP) was evaluated by insertion in vitro into porcine skin. After a predetermined attachment time, the remaining height of the X-linked HA-NP-MAP was measured to determine the dissolution rate. X-linked HA-NP-MAP and free HA-MAP containing Rhodamine B isothiocyanate-dextran were administered into the back skin of mice, and the relative fluorescent intensity in the back skin was measured over time. RESULTS: The puncture performance of the X-linked HA-NP-MAP was over 90%. The diameter of redispersed X-linked HA-NPs was same as that of the premolded X-linked HA-NPs. The dissolution rate was not different from that of free HA-MAP. In an in vivo experiment, X-linked HA-NP-MAP was administered into the mouse's back skin successfully and the relative fluorescent intensity of X-linked HA-NP-MAP lasted longer than that of HA-MAP. CONCLUSION: X-linked HA-NPs provide the biocompatibility, the processability of micromolding, sustained drug release, successful penetration into the skin, and relatively short insertion time for full disintegration of NPs in the skin. X-linked HA-NP-MAP can be used for various applications that require several days of sustained drug release.
AIMS: Crosslinked hyaluronic acid (X-linked HA) is not suitable for making microneedles because of the low fluidity of X-linked HA hydrogel. Microneedles were fabricated using X-linked HA nanoparticles (X-linked HA-NPs) to utilize the sustained drug delivery capability of X-linked HA-NPs and to obtain the processability advantages of X-linked HA. METHOD: The puncture performance of a microneedle array patch (MAP) made of crosslinked hyaluronic acid nanoparticles (X-linked HA-NP-MAP) was evaluated by insertion in vitro into porcine skin. After a predetermined attachment time, the remaining height of the X-linked HA-NP-MAP was measured to determine the dissolution rate. X-linked HA-NP-MAP and free HA-MAP containing Rhodamine B isothiocyanate-dextran were administered into the back skin of mice, and the relative fluorescent intensity in the back skin was measured over time. RESULTS: The puncture performance of the X-linked HA-NP-MAP was over 90%. The diameter of redispersed X-linked HA-NPs was same as that of the premolded X-linked HA-NPs. The dissolution rate was not different from that of free HA-MAP. In an in vivo experiment, X-linked HA-NP-MAP was administered into the mouse's back skin successfully and the relative fluorescent intensity of X-linked HA-NP-MAP lasted longer than that of HA-MAP. CONCLUSION: X-linked HA-NPs provide the biocompatibility, the processability of micromolding, sustained drug release, successful penetration into the skin, and relatively short insertion time for full disintegration of NPs in the skin. X-linked HA-NP-MAP can be used for various applications that require several days of sustained drug release.
Authors: Abeer M Al-Ghananeem; Ahmad H Malkawi; Yahya M Muammer; Justin M Balko; Esther P Black; Walid Mourad; Edward Romond Journal: AAPS PharmSciTech Date: 2009-04-21 Impact factor: 3.246
Authors: Joakim Kennedy; Eneko Larrañeta; Maelíosa T C McCrudden; Cian M McCrudden; Aaron J Brady; Steven J Fallows; Helen O McCarthy; Adrien Kissenpfennig; Ryan F Donnelly Journal: J Control Release Date: 2017-04-17 Impact factor: 9.776
Authors: Maelíosa T C Mc Crudden; Eneko Larrañeta; Annie Clark; Courtney Jarrahian; Annie Rein-Weston; Sophie Lachau-Durand; Nico Niemeijer; Peter Williams; Clement Haeck; Helen O McCarthy; Darin Zehrung; Ryan F Donnelly Journal: J Control Release Date: 2018-11-02 Impact factor: 9.776
Authors: Maciej Jarzębski; Przemysław Siejak; Monika Przeor; Jacek Gapiński; Anna Woźniak; Hanna Maria Baranowska; Jarosław Pawlicz; Elżbieta Baryła-Pankiewicz; Anna Szwajca Journal: Molecules Date: 2020-04-25 Impact factor: 4.411